This HTML5 document contains 82 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
dcthttp://purl.org/dc/terms/
dbohttp://dbpedia.org/ontology/
foafhttp://xmlns.com/foaf/0.1/
dbpedia-eshttp://es.dbpedia.org/resource/
n12https://global.dbpedia.org/id/
dbthttp://dbpedia.org/resource/Template:
rdfshttp://www.w3.org/2000/01/rdf-schema#
n13http://www.ontologydesignpatterns.org/ont/dul/DUL.owl#
n9http://commons.wikimedia.org/wiki/Special:FilePath/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
wikipedia-enhttp://en.wikipedia.org/wiki/
dbphttp://dbpedia.org/property/
dbchttp://dbpedia.org/resource/Category:
provhttp://www.w3.org/ns/prov#
xsdhhttp://www.w3.org/2001/XMLSchema#
wikidatahttp://www.wikidata.org/entity/
dbrhttp://dbpedia.org/resource/

Statements

Subject Item
dbr:List_of_investigational_analgesics
dbo:wikiPageWikiLink
dbr:Olorinab
Subject Item
dbr:C18H24N5O3
dbo:wikiPageWikiLink
dbr:Olorinab
dbo:wikiPageRedirects
dbr:Olorinab
Subject Item
dbr:Tedalinab
dbo:wikiPageWikiLink
dbr:Olorinab
Subject Item
dbr:Olorinab
rdf:type
wikidata:Q8386 dbo:Drug n13:ChemicalObject dbo:ChemicalSubstance owl:Thing
rdfs:label
Olorinab Olorinab
rdfs:comment
El olorinab (APD371) es un medicamento desarrollado por Arena Pharmaceuticals para el tratamiento del dolor gastrointestinal asociado con la enfermedad de Crohn y el síndrome del intestino irritable.​ Actúa como un potente y selectivo agonista de los receptores cannabinoides CB2 y se afirma que es oralmente activo y periféricamente selectivo.​​ Olorinab (APD371) is a drug being developed by Arena Pharmaceuticals for the treatment of gastrointestinal pain associated with Crohn's disease and irritable bowel syndrome. It acts as a potent and selective cannabinoid CB2 receptor agonist and is claimed to be orally active and peripherally selective. Initial Phase IIa exploratory clinical trials have been successful in patients with quiescent Crohn's disease. Arena initiated the Phase IIb Captivate trial in late July 2019 in patients with irritable bowel syndrome related pain, in constipation and diarrhea predominant sub-types. The Phase IIb trial is expected to enroll 240 participants between the ages of 18 to 70.Three doses of 10 mg, 25 mg, and 50 mg are being tested against Placebo in a 3:4 prescription ratio with a Quadruple (Partici
foaf:depiction
n9:Olorinab.svg
dct:subject
dbc:Tert-butyl_compounds dbc:Experimental_drugs dbc:Cannabinoids dbc:Pyrazines dbc:Carboxamides dbc:Peripherally_selective_drugs dbc:Pyrazoles
dbo:wikiPageID
58483282
dbo:wikiPageRevisionID
1089324462
dbo:wikiPageWikiLink
dbr:MDMB-FUBINACA dbr:Placebo dbc:Tert-butyl_compounds dbr:Arena_Pharmaceuticals dbr:Mechanism_of_action dbr:Agonist dbc:Cannabinoids dbc:Experimental_drugs dbr:Tedalinab dbr:Nociception dbr:Irritable_bowel_syndrome dbc:Peripherally_selective_drugs dbc:Pyrazines dbr:NESS-040C5 dbr:SR-144,528 dbc:Carboxamides dbr:Cannabinoid_receptor_2 dbr:Cannabinoid dbr:Crohn's_disease dbc:Pyrazoles dbr:Clinical_trial dbr:Receptor_(biochemistry) dbr:Drug_development
owl:sameAs
n12:7WAMh wikidata:Q56615642 dbpedia-es:Olorinab
dbp:wikiPageUsesTemplate
dbt:Fdacite dbt:Drugbox dbt:Cannabinoid_receptor_modulators dbt:Cannabinoids dbt:Cannabinoid-stub dbt:Short_description
dbo:thumbnail
n9:Olorinab.svg?width=300
dbp:c
18
dbp:casNumber
1268881
dbp:h
23
dbp:iupacName
-N--1--4,4a,5,5a-tetrahydro-1H-cyclopropacyclopenta[1,2-c]pyrazole-3-carboxamide
dbp:kegg
D11429
dbp:n
5
dbp:o
3
dbp:pubchem
60164925
dbp:routesOfAdministration
Oral
dbp:smiles
CC[C@@H]NCC1=NNC4=NC=C[N+][O-]
dbp:stdinchi
1
dbp:stdinchikey
ACSQLTBPYZSGBA-GMXVVIOVSA-N
dbp:unii
581
dbp:width
200
dbo:abstract
El olorinab (APD371) es un medicamento desarrollado por Arena Pharmaceuticals para el tratamiento del dolor gastrointestinal asociado con la enfermedad de Crohn y el síndrome del intestino irritable.​ Actúa como un potente y selectivo agonista de los receptores cannabinoides CB2 y se afirma que es oralmente activo y periféricamente selectivo.​​ Los ensayos clínicos exploratorios iniciales de fase IIa han tenido éxito en pacientes que padecen la enfermedad de Crohn inactiva. ​ Arena inició el ensayo de Fase IIb Captivate ​ a fines de julio de 2019 ​ en pacientes que sufren dolor relacionado con el síndrome del intestino irritable, subtipos predominantes de estreñimiento y diarrea.​ Se espera que el ensayo de Fase IIb inscriba a 240 participantes entre las edades de 18 a 70. Se están probando tres dosis de 10 mg, 25 mg y 50 mg contra Placebo en una proporción de 3:4 con una disposición de enmascaramiento cuádruple (participante, proveedor de cuidados, investigador, evaluador de resultados). ​ ​ En 2019 un estudio demostró que el Olorinab reduce la hipersensibilidad visceral en el modelo animal de colitis inducida por la TNBS, intentando controlar su mecanismo de acción mediante el uso de un antagonista del CB2. Los resultados fueron favorables mostrando una reducción de la hipersensibilidad visceral en modelos animales de EII y SII pero no en los controles sanos, sugiriendo que la activación del CB2 causa acciones antinociceptivas en las vías sensoriales viscerales en modelos de EII y SII. También la SR-144528 previno la inhibición inducida por el olorinab de la hipersensibilidad del nociceptor colónico, validando aún más el papel del receptor CB2 en la nocicepción ​ Olorinab (APD371) is a drug being developed by Arena Pharmaceuticals for the treatment of gastrointestinal pain associated with Crohn's disease and irritable bowel syndrome. It acts as a potent and selective cannabinoid CB2 receptor agonist and is claimed to be orally active and peripherally selective. Initial Phase IIa exploratory clinical trials have been successful in patients with quiescent Crohn's disease. Arena initiated the Phase IIb Captivate trial in late July 2019 in patients with irritable bowel syndrome related pain, in constipation and diarrhea predominant sub-types. The Phase IIb trial is expected to enroll 240 participants between the ages of 18 to 70.Three doses of 10 mg, 25 mg, and 50 mg are being tested against Placebo in a 3:4 prescription ratio with a Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) masking layout. In 2019, a study showed that Olorinab reduces Visceral Hypersensitivity in the TNBS-induced colitis animal model, attempting to control for its mechanism of action by using a CB2 antagonist (SR-144,528). Results were favorable showing reduced visceral hypersensitivity in animal models of IBD and IBS but not in healthy controls, suggesting that activation of CB2 causes antinociceptive actions in visceral sensory pathways in models of IBD and IBS. Also, SR-144528 prevented olorinab-induced inhibition of colonic nociceptor hypersensitivity, further validating the role of the CB2 receptor in nociception.
prov:wasDerivedFrom
wikipedia-en:Olorinab?oldid=1089324462&ns=0
dbo:wikiPageLength
6364
dbo:casNumber
1268881-20-4
dbo:fdaUniiCode
581F7DFA9B
dbo:kegg
D11429
dbo:pubchem
60164925
foaf:isPrimaryTopicOf
wikipedia-en:Olorinab
Subject Item
dbr:APD371
dbo:wikiPageWikiLink
dbr:Olorinab
dbo:wikiPageRedirects
dbr:Olorinab
Subject Item
wikipedia-en:Olorinab
foaf:primaryTopic
dbr:Olorinab